Reduced levels of N-terminal-proatrial natriuretic peptide in hypertensive patients with metabolic syndrome and their relationship with left ventricular mass

2007 ◽  
Vol 25 (4) ◽  
pp. 833-839 ◽  
Author(s):  
Speranza Rubattu ◽  
Sebastiano Sciarretta ◽  
Giuseppino Massimo Ciavarella ◽  
Vanessa Venturelli ◽  
Paola De Paolis ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Left Ventricular Mass ◽  
Natriuretic Peptide ◽  
Left Ventricular ◽  
Hypertensive Patients ◽  
Ventricular Mass

scholarly journals The association of left ventricular mass index with metabolic syndrome in comparison to hypertensive patients

2016 ◽  
Vol 26 (2) ◽  
pp. 42 ◽  
Author(s):  
RajeshK Gupta ◽  
Rimzim Gupta ◽  
Neeraj Makar ◽  
Shashank Chaudhary ◽  
Himanshu Bhatheja ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Left Ventricular Mass ◽  
Left Ventricular Mass Index ◽  
Left Ventricular ◽  
Hypertensive Patients ◽  
Ventricular Mass Index ◽  
Ventricular Mass

scholarly journals Relationships between metabolic syndrome and left ventricular mass in hypertensive patients: does sex matter?

2008 ◽  
Vol 22 (11) ◽  
pp. 788-795 ◽  
Author(s):  
G Mulè ◽  
P Cusimano ◽  
E Nardi ◽  
S Cottone ◽  
C Geraci ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Left Ventricular Mass ◽  
Left Ventricular ◽  
Hypertensive Patients ◽  
Ventricular Mass

scholarly journals Myocardial hipertrophy in hypertensive patients with and without metabolic syndrome

2008 ◽  
Vol 65 (11) ◽  
pp. 830-834 ◽  
Author(s):  
Branislava Ivanovic ◽  
Dane Cvijanovic ◽  
Marija Tadic ◽  
Dragan Simic
Keyword(s):  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Drug Treatment ◽  
Arterial Hypertension ◽  
Left Ventricular Mass ◽  
Left Ventricular ◽  
Control Group ◽  
Hypertensive Patients ◽  
Ventricular Mass ◽  
Significant Difference

Background/Aim. Beside arterial hypertension as the most important factor of a myocardial hypertension development, very important risk factors are obesity, hypercholesterolemia, insulin resistance, etc. The aim of the study was to examine the influence of metabolic syndrome (MetS) on left ventricular hypertrophy in patients with arterial hypertension. Methods. We checked medical records for 138 patients with arterial hypertension, and compared them with the control group of 44 normotensive subjects. The patients with arterial hypertension were divided into two groups considering the presence of MetS: with MetS (59 patients), and without MetS (79 patients). We defined MetS as presence of three (or more) within five criteria: central obesity (> 102 cm male, > 88 cm female), raised triglycerides (> 1.7 mmol/L, or drug treatment for elevated triglycerides), reduced high density lipoprotein (HDL) cholesterol (< 1.03 mmol/L male, < 1.3 mmol/L female), raised blood pressure (> 130 mmHg systolic, > 90 mmHg diastolic), raised fasting glucose (> 6.11 mmol/L, or drug treatment for elevated glucose level). In each group routine laboratory, echocardiography and 24-hour ambulatory blood pressure monitoring were performed. Results. We found statisticaly significant higher left ventricular mass in both subgroups hypertensive patients in comparison with the control group (p < 0.05). We did not find statistically significant difference (227.31?63.44 vs 219?59.5, p > 0.05) in left ventricular mass between these two groups of patients. In the patients with arterial hypertension and MetS we found hypertrophy more frequently than in the subgroup without MetS (43/57 vs 34/69, p < 0.001). Conclusion. Our results suggest that associated cardiometabolic risks increase the prevalence of myocardial hypertrophy, but do not influence left ventricular mass.

Sign in / Sign up

Export Citation Format

Share Document